Entrada Quarterly Newsletter for the Duchenne Community

August 6, 2025

At Entrada, we understand that every clinical update is more than just news for the Duchenne community—it's a measure of hope. That's why we're committed to providing clear, timely and transparent updates on the progress of our Duchenne programs.

As part of our ongoing commitment, we're pleased to introduce the first issue of our new quarterly community newsletter. **To receive future updates and newsletters directly in your inbox, click here.**

Many thanks to the Wang family (pictured above) for sharing their story with us and kindly allowing us to feature their photo in this issue!

News Spotlitght:

Today we announced that the first patient has been dosed in our ELEVATE-44-201 study.
Read our August 6, 2025 news release for more details.

Updates on Clinical Studies:

Enabled by our Endosomal Escape Vehicle (EEV™) platform, we are working to quickly advance our lead programs for people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Read on for our progress.

Exon 44 Skipping Amenable Community

ELEVATE-44-201 Study: Now Enrolling Participants

The ELEVATE-44-201 study is a global, randomized, double-blind placebo-controlled* Phase 1/2 study evaluating the safety, tolerability and effectiveness of ENTR-601-44 in ambulatory children and young adults living with Duchenne who are amenable to exon 44 skipping. The study is now enrolling participants and is taking place in the U.K., Belgium, Italy and Spain. We expect to share data from the first cohort of participants in the first half of 2026. To learn more about the study and participation, visit www.elevate44study.com.

ELEVATE-44-102 Study: Expected to Start in the U.S. in the First Half of 2026

The ELEVATE-44-102 study is a randomized, double-blind placebo-controlled* Phase 1b study evaluating the safety and tolerability of ENTR-601-44 in non-ambulatory and ambulatory adults living with Duchenne who are amenable to exon 44 skipping. This study will take place in the U.S.

Exon 45 Skipping Amenable Community

> ***ELEVATE-45-201 Study: Now Enrolling Participants***
>
> The ELEVATE-45-201 study is a global, randomized, double-blind placebo-controlled* Phase 1/2 study evaluating the safety, tolerability and effectiveness of ENTR-601-45 in ambulatory children and young adults living with Duchenne who are amenable to exon 45 skipping. The study is enrolling participants and will take place in the U.K., the Netherlands, Belgium, Italy and Spain. We are on track to dose the first patient in the third quarter of 2025. To learn more about the study and participation, visit www.elevate45study.com.

Exon 50 Skipping Amenable Community

> We expect to submit global regulatory filings to begin a Phase 1/2 study of ENTR-601-50 in the U.K. and EU in Q4 2025.

Exon 51 Skipping Amenable Community

> We expect to submit global regulatory filings to begin a Phase 1/2 study of ENTR-601-51 in the U.K. and EU in 2026.

* A placebo looks like a study drug but does not have any medicine in it. Researchers use placebos to help make sure any changes in participants' health are actually caused by the study drug.

Meet the Entrada Patient Advocacy Team:

Sarah Friedhoff

As our Head of Patient Advocacy at Entrada, Sarah is responsible for ensuring the needs, preferences and insights of the community shape the decisions made in our Board room and drive change throughout every phase of our development.

Fun Fact!

Sarah's been to five out of seven continents (and is hoping to make it to the remaining two—Africa and Antarctica—in the next decade!)

Owen Erickson

As our Associate, Patient Advocacy and Corporate Affairs, Owen is responsible for implementing Entrada's digital strategy as well as developing materials and working with stakeholders to build meaningful connections with the communities we aim to serve.

Fun Fact!

Owen plays competitive ultimate frisbee in his free time (and previously captained and coached his college team—go Bees!)

Karla MacDonald

As Entrada's Chief Corporate Affairs Officer, Karla oversees Entrada's Patient Advocacy team and champions the company's steadfast commitment to patient-focused drug development.

Fun Fact!

Karla's parents are from a lobster fishing village in Nova Scotia, Canada. Her first job as a kid was to catch (or as they say "jig for") mackerel, providing bait to the lobster traps.

Recent Community Events:

In June, we sponsored and attended Parent Project Muscular Dystrophy's 2025 Annual Conference in Las Vegas. Thanks to the Studebaker family for graciously allowing us to feature this photo from the PPMD conference in this issue!

In May, we sponsored and attended the CureDuchenne FUTURES National Conference in San Antonio, as well as the International Duchenne Congress, hosted by Duchenne Parent Project España. *Pictured: Karla presenting at the CureDuchenne FUTURES meeting.*

Upcoming Events:

We support, participate in and hold events to connect with the community and work toward solutions together. Here's what we're up to for the next few months:

August 10-14:

> Jett Foundation's Camp Promise East
> *Brackney, PA, U.S.*

August 20:

> MDA's Summer Camp
> *Hardwick, NJ, U.S.*

September 6:

> Jett Foundation's World Duchenne Awareness Day Luncheon
> *Quincy, MA, U.S.*

September 7:

> Entrada 2025 DREAMS Grant Program
> Recipients Announced – *Virtual*

September 26-27:

> 2025 SMDF Symposium
> *Stockholm, Sweden*

September 27:

> Hope for Gus' Moving Mountains for Duchenne Fundraiser
> *Crotched Mountain, NH, U.S.*

> Duchenne Parent Project Belgium's Duchenne and Becker Congress
> *Haacht, Belgium*

We'd love to connect with you.

Contact Sarah Friedhoff, our Head of Patient Advocacy, at patientadvocacy@entradatx.com.

*This document includes forward-looking statements that involve risks and uncertainties. These statements are not guarantees of future results and should not be used for investment decisions.